Chengdu Guowei Pharmaceutical Technology

Chengdu Guowei Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Chengdu, China, focused on the discovery and development of innovative small molecule therapeutics. Established in 2014, the company primarily targets metabolic disorders and oncology, leveraging its expertise in medicinal chemistry and drug design. Its lead candidate, GW-001, is a potent GPR119 agonist currently undergoing Phase 2 clinical trials for the treatment of type 2 diabetes. In addition to its metabolic pipeline, the company is advancing several preclinical programs in the oncology space, utilizing technologies such as deuterium substitution to improve drug profiles. Chengdu Guowei operates out of the Chengdu Hi-tech Zone and maintains collaborations with local academic institutions to drive its R&D efforts. The company aims to provide effective and affordable treatment options for patients with chronic diseases.